Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122061 | 0.85 | ALDH1A1 (0.50) | MEP1BPTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL14122064 | 0.85 | ALDH1A1 (0.50) | MEP1BPTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL14122286 | 0.85 | ALDH1A1 (0.50) | MEP1BPTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL1125437 | 0.84 | CYP2C9 (0.50) | PPARGPPARAMEP1BPTGESKMT2A | |
| SCHEMBL3921799 | 0.84 | CYP2C9 (0.50) | PPARGPPARAMEP1BPTGESKMT2A | |
| SCHEMBL14157516 | 0.81 | FFAR4 (0.39) | PPARGPPARAKMT2AALDH1A1 | |
| SCHEMBL4496522 | 0.81 | PLG (0.46) | PPARGPPARAMEP1BPTGESMEN1 | |
| SCHEMBL11713591 | 0.80 | HSD17B10 (0.52) | PPARGPPARAPTGS1KMT2AALDH1A1 | |
| SCHEMBL14241528 | 0.80 | CYP4F2 (0.40) | MEP1BPTGESMEN1KMT2AALDH1A1 | |
| SCHEMBL14241529 | 0.80 | CYP4F2 (0.40) | MEP1BPTGESMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9051265-B2 | N-benzylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2012170561-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4163/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4163/4885 |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | PPARG, CDK5R1, CDK5 | PPARG 1/4885PPARA 5/4885MEP1B 4681/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4188/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4188/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4188/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEP1B 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.